Developer docs
API playgroundTry for free, no card

Search company profiles

Nihon Generic

Full company profile

uuid0029c8a

Namestring
Nihon Generic
Legal namestring
日本ジェネリック株式会社
Company typeenum
Private
Founded yearint
2005
Descriptiontext

Nihon Generic Co., Ltd. (日本ジェネリック株式会社) is a Japan-based generic pharmaceutical manufacturer founded on January 5, 2005, and operating as a wholly-owned subsidiary of Nichi-Iko Pharmaceutical Co., Ltd. The company manufactures and supplies generic medicines for the Japanese market, with 384 catalog items of which 159 are manufactured in-house at its Tsukuba and Tsukuba Second factories as of March 2026, and the remainder distributed. Its product portfolio spans multiple therapeutic categories and includes both prescription generics and, since 2024, an over-the-counter Minoxidil 5% formulation. Recent launches have prioritized higher-complexity molecules such as Tacrolimus, Bosentan, Abiraterone, Lacosamide, and Rivaroxaban.

The company operates a GMP-compliant manufacturing base in Tsukuba (Ibaraki Prefecture), supported by a nationwide logistics network including a West Japan Logistics Center in Sanda City, Hyogo, and a headquarters relocated to Tamachi Station Tower S in Tokyo in September 2024. It holds ISO 14001 environmental management certification. Production is concentrated in two factories that the company describes as forming a 'generic medicine town.' The workforce stood at 556 employees as of June 1, 2026, and registered capital is ¥100 million. In November 2021, the company expanded its manufacturing base through the acquisition of Choseido Pharmaceutical Co., Ltd.

Nihon Generic's revenue model is a B2B sale of generic pharmaceuticals to wholesalers, hospitals, clinics, and pharmacies, with distribution tightly integrated into the Nichi-Iko pharmacy network. Pricing follows Japanese generic reimbursement rules, with revenue tied to volume dispensed and periodic government-led price revisions. The OTC Minoxidil product adds a consumer-channel revenue line sold through retail pharmacies at a fixed retail price. Customer concentration sits primarily with the Nichi-Iko parent pharmacy channel for prescription volume, partially offset by wholesale distribution and the OTC line.

Short descriptiontext

Nihon Generic is a Japan-based generic pharmaceutical manufacturer and wholly-owned subsidiary of Nichi-Iko Pharmaceutical. It manufactures 159 of its 384 catalog products in-house at two Tsukuba factories, distributing generic medicines and OTC products to pharmacies, wholesalers, and medical institutions across Japan.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersMarunouchi, Japan
HQ citystring
Marunouchi
HQ countrystring
Japan
HQ regionstring
Asia
Markets served

Serves global market

Offices7 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
generic pharmaceuticals, prescription drug manufacturing, OTC medications, GMP-compliant production, pharmaceutical distribution
Industry3 codes
PRIMARYHLAIABAH
Generic Finished Dosage Form (FDF) Manufacturing
SECONDARYHLAIABAD
Oral Solid Dose (OSD) Generics
SECONDARYHLAIABAA
Small-Molecule Generics (Branded/Unbranded)
NAICS code4 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Pharmaceutical and Medicine Manufacturing32541
  • Drugs and Druggists' Sundries Merchant Wholesalers424210
  • Drugs and Druggists' Sundries Merchant Wholesalers42421
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Wholesale-Drugs, Proprietaries & Druggists' Sundries5122
Product category
Generic Pharmaceuticals
No data
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1Prescription Generic Pharmaceutical Products
TypeOne Time License
Description

Revenue from manufacturing and selling generic pharmaceutical products (generics) to medical institutions, hospitals, and pharmacies across Japan. The company handles 384 product items (as of March 2026) and manufactures 159 product items including commissioned products.

nihon-generic.co.jp
2OTC Pharmaceutical Products
TypeOne Time License
Description

Revenue from over-the-counter pharmaceutical products sold directly to consumers through pharmacies, such as the Minoxidil Lotion 5% 'JG' for hair growth treatment.

nihon-generic.co.jp
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Operations, Supply Chain, Technology or R&D, Marketing or Sales, Infrastructure
Pricing details1 tier
1Minoxidil Lotion 5% 'JG' - First-class OTC pharmaceutical product for hair growth
ModelOne time/ perpetual licenseBilling cadenceOne time/ perpetual license
Notes

Sold as a first-class OTC pharmaceutical product through pharmacies with pharmacist consultation. Specific pricing not disclosed in available sources.

nihon-generic.co.jp
GTM typeB2B and B2C
B2B and B2C
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Nihon Generic manufactures and sells generic pharmaceutical products to medical institutions and pharmacies across Japan. The company operates an integrated R&D, manufacturing, and distribution model producing both prescription generics (covering cardiovascular, antineoplastic, CNS, diabetes, respiratory, and other therapeutic categories) and OTC products such as Minoxidil Lotion 5% 'JG' for hair growth. It runs GMP-compliant Tsukuba manufacturing facilities and supplies 384+ product items nationwide through eight regional branches and three logistics centers.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 value
  • 384品目 handling capacity, 159品目 manufacturing capacity
Product overview1 text field

Nihon Generic operates as a generic pharmaceutical company within the Japan Nichido Pharmaceutical Group, manufacturing and distributing prescription and over-the-counter generic medications. The company maintains an integrated business model spanning research and development, manufacturing, and sales distribution. Their prescription product portfolio exceeds 384 items covering diverse therapeutic categories including immunosuppressants (Tacrolimus capsules), cardiovascular medications (Bosentan, Rivaroxaban), antineoplastic agents (Abiraterone), antiepileptics (Lacosamide, Lamotrigine), and diabetes treatments (BIldagliptin). The OTC division offers the Minoxidil lotion 5% for hair loss treatment. Manufacturing is conducted at company facilities in Tsukuba City (Tsukuba Plant, Tsukuba Second Plant), with a subsidiary Choseido Pharmaceutical contributing additional products. The company distributes through a nationwide logistics network including East Japan, West Japan, and Sapporo logistics centers.

Product and service13 records
1Minoxidil Lotion 5% 'JG'
CategoryOver-the-counter pharmaceutical product
Description

First-class OTC medication for treating adult male androgenetic alopecia (androgenic hair loss). The active ingredient minoxidil dilates hair follicle blood vessels to promote hair growth. Applied topically twice daily. Sold through pharmacies with mandatory pharmacist consultation.

2Tacrolimus capsules 0.5mg/1mg/5mg 'JG'
CategoryPrescription pharmaceutical product
Description

Generic immunosuppressant medication used for preventing organ rejection after transplantation and treating autoimmune conditions. Additional efficacy and dosage approval obtained in June 2026.

3Bosentan tablets 62.5mg 'JG'
CategoryPrescription pharmaceutical product
Description

Generic endothelin receptor antagonist indicated for treating pulmonary arterial hypertension. Additional approval for expanded indication obtained in March 2026.

4Abiraterone acetate tablets 250mg 'JG'
CategoryPrescription pharmaceutical product
Description

Generic antineoplastic agent (hormone antagonist) for treating prostate cancer. Launched December 2025.

5Lacosamide tablets 50mg/100mg 'JG' and Lacosamide dry syrup 10% 'JG'
CategoryPrescription pharmaceutical product
Description

Generic antiepileptic medication for treating partial-onset seizures. Additional indication approved December 2025.

6Rivaroxaban OD tablets 10mg/15mg 'JG'
CategoryPrescription pharmaceutical product
Description

Generic direct oral anticoagulant (DOAC) for treating and preventing venous thromboembolism, available as orally disintegrating tablets. Launched December 2024.

7Ezenlos combination tablets LD/HD 'JG'
CategoryPrescription pharmaceutical product
Description

Generic combination antihypertensive medication launched in December 2024.

8BIldagliptin tablets 50mg 'JG'
CategoryPrescription pharmaceutical product
Description

Generic DPP-4 inhibitor antidiabetic medication for type 2 diabetes treatment. Launched December 2024.

9Taltanlan OD tablets 250mg/500mg 'FCI'
CategoryPrescription pharmaceutical product
Description

Generic lanthanum carbonate chewable tablets for chronic kidney disease patients requiring phosphate control. Launched December 2024.

10Ambrisentan tablets 2.5mg 'JG'
CategoryPrescription pharmaceutical product
Description

Generic endothelin receptor antagonist for pulmonary arterial hypertension treatment. Launched December 2023.

11Ezestat combination tablets LD/HD 'JG'
CategoryPrescription pharmaceutical product
Description

Generic combination medication for hypertension treatment. Launched September 2023.

12Budeside inhaled powder 30/60 inhalations 'JG'
CategoryPrescription pharmaceutical product
Description

Generic inhaled corticosteroid for treating respiratory conditions such as asthma and COPD. Subject to FAQ support for medical professionals via the medical portal.

13Generic pharmaceutical product portfolio (384+ items)
CategoryPrescription pharmaceutical portfolio
Description

Portfolio of 384+ generic pharmaceutical products covering multiple therapeutic categories including cardiovascular drugs, antineoplastics, anti-infectives, CNS medications, diabetes treatments, and respiratory drugs. The company handles 384 product items as of March 2026 and manufactures 159 product items including commissioned products. The portfolio is managed end-to-end from development through manufacturing and sales.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
1Japan Tego Co., Ltd. (日本调配株式会社)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-11-01
Description

Parent company and core strategic partner. Japan Tego operates a nationwide pharmacy chain and provides patient feedback that Nihon Generic incorporates into product development.

nihon-generic.co.jp
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Part of Japan Tego Group, providing medical staffing and placement services for healthcare professionals.

3Choseido Pharmaceutical Co., Ltd. (長生堂製薬株式会社)
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Subsidiary acquired in November 2021, expanding manufacturing capacity and product portfolio. Operates Kawauchi Factory.

nihon-generic.co.jp
4Japan Pharmaceutical Comprehensive Research Institute Co., Ltd. (株式会社日本医薬総合研究所)
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Part of Japan Tego Group, provides pharmaceutical consulting services.

nihon-generic.co.jp
5Japan Generic Pharmaceutical Association (日本ジェネリック製薬協会/JGA)
Strategic tierMinorTypeOthers
Description

Industry association for generic pharmaceutical companies in Japan. Nihon Generic is a member.

nihon-generic.co.jp
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
1Nichi-Iko Pharmaceutical
TypeDirect peer
Description

One of the leading Japanese generic manufacturers, offering a comprehensive generics portfolio plus biosimilars. Comparable in business model (NHI-priced generics) and customer base, with broader scale and a more diversified product mix than Nihon Generic.

2Sawai Pharmaceutical
TypeDirect peer
Description

One of Japan's largest generic pharmaceutical manufacturers, with a broad portfolio of oral solid dose generics and nationwide distribution. Directly comparable to Nihon Generic in product category, customer base (medical institutions and pharmacies), and NHI-regulated business model, but at materially greater scale.

3Choseido Pharmaceutical
TypeDirect peer
Description

Wholly-owned subsidiary of Nihon Generic since November 2021, operating the Kawauchi Factory and producing generic pharmaceuticals. Same business model and target customer base as Nihon Generic, providing manufacturing capacity and additional SKUs.

4Medipal Holdings
TypeBroad incumbent
Description

One of Japan's largest pharmaceutical wholesalers, distributing prescription drugs including generics across the country. Overlaps with Nihon Generic in serving the same hospital and pharmacy customers via different channels.

5Towa Pharmaceutical
TypeDirect peer
Description

Major Japanese generic drug manufacturer focused on oral solid dose generics, with extensive manufacturing capacity and a portfolio of 800+ items. Directly competes with Nihon Generic across the same therapeutic categories and pharmacy/hospital channels in Japan.

6Meiji Seika Pharma
TypeBroad incumbent
Description

Established Japanese pharmaceutical company with a generics business alongside branded specialty drugs. Overlaps with Nihon Generic in generic hospital and institutional products but operates at substantially larger scale and with a broader therapeutic footprint.

7Alfresa Corporation
TypeBroad incumbent
Description

Major Japanese pharmaceutical wholesaler distributing both branded and generic drugs to hospitals and pharmacies nationwide. Comparable as a downstream distribution channel and supply chain intermediary that competes indirectly with Nihon Generic's own distribution function.

8Tsumura & Co.
TypeBroad incumbent
Description

Established Japanese pharmaceutical manufacturer primarily focused on Kampo (traditional herbal) medicines but also produces prescription pharmaceuticals. Comparable as a domestic Japanese pharma manufacturer operating under similar regulatory frameworks, though with a differentiated product focus.

9Suzuken
TypeBroad incumbent
Description

Major Japanese pharmaceutical wholesaler with nationwide distribution to medical institutions and pharmacies. Comparable as a distribution intermediary serving the same end customers as Nihon Generic's prescription generics business.

10Nichiko Pharmaceutical
TypeOthers
Description

Parent company of Nihon Generic and one of Japan's largest dispensing pharmacy chains. Comparable through shared ownership and a vertically integrated business model that channels pharmacy demand signals into Nihon Generic's product development.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature2 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Nihon Generic

Generic Pharmaceuticalsnihon-generic.co.jp

Nihon Generic is a Japan-based generic pharmaceutical manufacturer and wholly-owned subsidiary of Nichi-Iko Pharmaceutical. It manufactures 159 of its 384 catalog products in-house at two Tsukuba factories, distributing generic medicines and OTC products to pharmacies, wholesalers, and medical institutions across Japan.

What Nihon Generic does

Nihon Generic Co., Ltd. (日本ジェネリック株式会社) is a Japan-based generic pharmaceutical manufacturer founded on January 5, 2005, and operating as a wholly-owned subsidiary of Nichi-Iko Pharmaceutical Co., Ltd. The company manufactures and supplies generic medicines for the Japanese market, with 384 catalog items of which 159 are manufactured in-house at its Tsukuba and Tsukuba Second factories as of March 2026, and the remainder distributed. Its product portfolio spans multiple therapeutic categories and includes both prescription generics and, since 2024, an over-the-counter Minoxidil 5% formulation. Recent launches have prioritized higher-complexity molecules such as Tacrolimus, Bosentan, Abiraterone, Lacosamide, and Rivaroxaban.

The company operates a GMP-compliant manufacturing base in Tsukuba (Ibaraki Prefecture), supported by a nationwide logistics network including a West Japan Logistics Center in Sanda City, Hyogo, and a headquarters relocated to Tamachi Station Tower S in Tokyo in September 2024. It holds ISO 14001 environmental management certification. Production is concentrated in two factories that the company describes as forming a 'generic medicine town.' The workforce stood at 556 employees as of June 1, 2026, and registered capital is ¥100 million. In November 2021, the company expanded its manufacturing base through the acquisition of Choseido Pharmaceutical Co., Ltd.

Nihon Generic's revenue model is a B2B sale of generic pharmaceuticals to wholesalers, hospitals, clinics, and pharmacies, with distribution tightly integrated into the Nichi-Iko pharmacy network. Pricing follows Japanese generic reimbursement rules, with revenue tied to volume dispensed and periodic government-led price revisions. The OTC Minoxidil product adds a consumer-channel revenue line sold through retail pharmacies at a fixed retail price. Customer concentration sits primarily with the Nichi-Iko parent pharmacy channel for prescription volume, partially offset by wholesale distribution and the OTC line.

Nihon Generic firmographics

Firmographics
Name
Nihon Generic
Legal name
日本ジェネリック株式会社
Website
https://nihon-generic.co.jp
Company type
Private
Founded year
2005
Operating status
Operating
Headcount range
1–10 employees
Short description
Nihon Generic is a Japan-based generic pharmaceutical manufacturer and wholly-owned subsidiary of Nichi-Iko Pharmaceutical. It manufactures 159 of its 384 catalog products in-house at two Tsukuba factories, distributing generic medicines and OTC products to pharmacies, wholesalers, and medical institutions across Japan.
Ownership category
akta.pro rank

Nihon Generic industry classification

Industry
Product category
Generic Pharmaceuticals
NAICS
Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (32541), Drugs and Druggists' Sundries Merchant Wholesalers (424210), Drugs and Druggists' Sundries Merchant Wholesalers (42421)
SIC
Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)
akta.pro industry
PRIMARYHLAIABAH
Generic Finished Dosage Form (FDF) Manufacturing
SECONDARYHLAIABAD
Oral Solid Dose (OSD) Generics
SECONDARYHLAIABAA
Small-Molecule Generics (Branded/Unbranded)

Keywords

  • Generic pharmaceuticals
  • Prescription drug manufacturing
  • OTC medications
  • GMP-compliant production
  • Pharmaceutical distribution

Where Nihon Generic is headquartered

Location

Headquarters

HQ city
Marunouchi
HQ country
Japan
HQ region
Asia

Offices7 records

Markets served

Nihon Generic business model

Business model
GTM type
B2B and B2C
Offering type
Hardware or Manufacturing
Cost components
Personnel, Operations, Supply Chain, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

  1. Prescription Generic Pharmaceutical Products: Revenue from manufacturing and selling generic pharmaceutical products (generics) to medical institutions, hospitals, and pharmacies across Japan. The company handles 384 product items (as of March 2026) and manufactures 159 product items including commissioned products.
  2. OTC Pharmaceutical Products: Revenue from over-the-counter pharmaceutical products sold directly to consumers through pharmacies, such as the Minoxidil Lotion 5% 'JG' for hair growth treatment.

Pricing tiers

ModelBillingPrice
One time/ perpetual licenseOne time/ perpetual licenseMinoxidil Lotion 5% 'JG' - First-class OTC pharmaceutical product for hair growth

Go-to-market motion2 records

Distribution channels3 records

Marketing channels4 records

Nihon Generic product offering

Product offering

Core offering

Nihon Generic manufactures and sells generic pharmaceutical products to medical institutions and pharmacies across Japan. The company operates an integrated R&D, manufacturing, and distribution model producing both prescription generics (covering cardiovascular, antineoplastic, CNS, diabetes, respiratory, and other therapeutic categories) and OTC products such as Minoxidil Lotion 5% 'JG' for hair growth. It runs GMP-compliant Tsukuba manufacturing facilities and supplies 384+ product items nationwide through eight regional branches and three logistics centers.

Product overview

Nihon Generic operates as a generic pharmaceutical company within the Japan Nichido Pharmaceutical Group, manufacturing and distributing prescription and over-the-counter generic medications. The company maintains an integrated business model spanning research and development, manufacturing, and sales distribution. Their prescription product portfolio exceeds 384 items covering diverse therapeutic categories including immunosuppressants (Tacrolimus capsules), cardiovascular medications (Bosentan, Rivaroxaban), antineoplastic agents (Abiraterone), antiepileptics (Lacosamide, Lamotrigine), and diabetes treatments (BIldagliptin). The OTC division offers the Minoxidil lotion 5% for hair loss treatment. Manufacturing is conducted at company facilities in Tsukuba City (Tsukuba Plant, Tsukuba Second Plant), with a subsidiary Choseido Pharmaceutical contributing additional products. The company distributes through a nationwide logistics network including East Japan, West Japan, and Sapporo logistics centers.

Differentiator

Problem solved

Functional benefit

Products and services

  • Minoxidil Lotion 5% 'JG' First-class OTC medication for treating adult male androgenetic alopecia (androgenic hair loss). The active ingredient minoxidil dilates hair follicle blood vessels to promote hair growth. Applied topically twice daily. Sold through pharmacies with mandatory pharmacist consultation.
  • Tacrolimus capsules 0.5mg/1mg/5mg 'JG' Generic immunosuppressant medication used for preventing organ rejection after transplantation and treating autoimmune conditions. Additional efficacy and dosage approval obtained in June 2026.
  • Bosentan tablets 62.5mg 'JG' Generic endothelin receptor antagonist indicated for treating pulmonary arterial hypertension. Additional approval for expanded indication obtained in March 2026.
  • Abiraterone acetate tablets 250mg 'JG' Generic antineoplastic agent (hormone antagonist) for treating prostate cancer. Launched December 2025.
  • Lacosamide tablets 50mg/100mg 'JG' and Lacosamide dry syrup 10% 'JG' Generic antiepileptic medication for treating partial-onset seizures. Additional indication approved December 2025.
  • Rivaroxaban OD tablets 10mg/15mg 'JG' Generic direct oral anticoagulant (DOAC) for treating and preventing venous thromboembolism, available as orally disintegrating tablets. Launched December 2024.
  • Ezenlos combination tablets LD/HD 'JG' Generic combination antihypertensive medication launched in December 2024.
  • BIldagliptin tablets 50mg 'JG' Generic DPP-4 inhibitor antidiabetic medication for type 2 diabetes treatment. Launched December 2024.
  • Taltanlan OD tablets 250mg/500mg 'FCI' Generic lanthanum carbonate chewable tablets for chronic kidney disease patients requiring phosphate control. Launched December 2024.
  • Ambrisentan tablets 2.5mg 'JG' Generic endothelin receptor antagonist for pulmonary arterial hypertension treatment. Launched December 2023.
  • Ezestat combination tablets LD/HD 'JG' Generic combination medication for hypertension treatment. Launched September 2023.
  • Budeside inhaled powder 30/60 inhalations 'JG' Generic inhaled corticosteroid for treating respiratory conditions such as asthma and COPD. Subject to FAQ support for medical professionals via the medical portal.
  • Generic pharmaceutical product portfolio (384+ items) Portfolio of 384+ generic pharmaceutical products covering multiple therapeutic categories including cardiovascular drugs, antineoplastics, anti-infectives, CNS medications, diabetes treatments, and respiratory drugs. The company handles 384 product items as of March 2026 and manufactures 159 product items including commissioned products. The portfolio is managed end-to-end from development through manufacturing and sales.

Quantifiable outcome

  • 384品目 handling capacity, 159品目 manufacturing capacity

Companies that use Nihon Generic

Customer profile

Named customers3 records

Segments3 records

Ideal customer profiles3 records

Nihon Generic technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature2 records

Nihon Generic partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered core and minor.

  • Japan Tego Co., Ltd. (日本调配株式会社)coreStrategic or Co-development Partner · 1 November 2021Parent company and core strategic partner. Japan Tego operates a nationwide pharmacy chain and provides patient feedback that Nihon Generic incorporates into product development.
  • Medical Resource Co., Ltd. (株式会社ニューロスペース)coreStrategic or Co-development PartnerPart of Japan Tego Group, providing medical staffing and placement services for healthcare professionals.
  • Choseido Pharmaceutical Co., Ltd. (長生堂製薬株式会社)coreStrategic or Co-development PartnerSubsidiary acquired in November 2021, expanding manufacturing capacity and product portfolio. Operates Kawauchi Factory.
  • Japan Pharmaceutical Comprehensive Research Institute Co., Ltd. (株式会社日本医薬総合研究所)minorStrategic or Co-development PartnerPart of Japan Tego Group, provides pharmaceutical consulting services.
  • Japan Generic Pharmaceutical Association (日本ジェネリック製薬協会/JGA)minorOthersIndustry association for generic pharmaceutical companies in Japan. Nihon Generic is a member.

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

Nihon Generic competitors and assessment

Company assessment

Direct peers

  • Nichi-Iko Pharmaceutical: One of the leading Japanese generic manufacturers, offering a comprehensive generics portfolio plus biosimilars. Comparable in business model (NHI-priced generics) and customer base, with broader scale and a more diversified product mix than Nihon Generic.
  • Sawai Pharmaceutical: One of Japan's largest generic pharmaceutical manufacturers, with a broad portfolio of oral solid dose generics and nationwide distribution. Directly comparable to Nihon Generic in product category, customer base (medical institutions and pharmacies), and NHI-regulated business model, but at materially greater scale.
  • Choseido Pharmaceutical: Wholly-owned subsidiary of Nihon Generic since November 2021, operating the Kawauchi Factory and producing generic pharmaceuticals. Same business model and target customer base as Nihon Generic, providing manufacturing capacity and additional SKUs.
  • Towa Pharmaceutical: Major Japanese generic drug manufacturer focused on oral solid dose generics, with extensive manufacturing capacity and a portfolio of 800+ items. Directly competes with Nihon Generic across the same therapeutic categories and pharmacy/hospital channels in Japan.

Broad incumbents

  • Medipal Holdings: One of Japan's largest pharmaceutical wholesalers, distributing prescription drugs including generics across the country. Overlaps with Nihon Generic in serving the same hospital and pharmacy customers via different channels.
  • Meiji Seika Pharma: Established Japanese pharmaceutical company with a generics business alongside branded specialty drugs. Overlaps with Nihon Generic in generic hospital and institutional products but operates at substantially larger scale and with a broader therapeutic footprint.
  • Alfresa Corporation: Major Japanese pharmaceutical wholesaler distributing both branded and generic drugs to hospitals and pharmacies nationwide. Comparable as a downstream distribution channel and supply chain intermediary that competes indirectly with Nihon Generic's own distribution function.
  • Tsumura & Co. Established Japanese pharmaceutical manufacturer primarily focused on Kampo (traditional herbal) medicines but also produces prescription pharmaceuticals. Comparable as a domestic Japanese pharma manufacturer operating under similar regulatory frameworks, though with a differentiated product focus.
  • Suzuken: Major Japanese pharmaceutical wholesaler with nationwide distribution to medical institutions and pharmacies. Comparable as a distribution intermediary serving the same end customers as Nihon Generic's prescription generics business.

Others

  • Nichiko Pharmaceutical: Parent company of Nihon Generic and one of Japan's largest dispensing pharmacy chains. Comparable through shared ownership and a vertically integrated business model that channels pharmacy demand signals into Nihon Generic's product development.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Nihon Generic compliance and trust

Trust signal

Compliance2 records

Nihon Generic financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Nihon Generic leadership team

Management profile

Number of profiles

Profiles1 record

Nihon Generic subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Nihon Generic funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Nihon Generic M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Nihon Generic

What does Nihon Generic do?

Nihon Generic manufactures and sells generic pharmaceutical products to medical institutions and pharmacies across Japan. The company operates an integrated R&D, manufacturing, and distribution model producing both prescription generics (covering cardiovascular, antineoplastic, CNS, diabetes, respiratory, and other therapeutic categories) and OTC products such as Minoxidil Lotion 5% 'JG' for hair growth. It runs GMP-compliant Tsukuba manufacturing facilities and supplies 384+ product items nationwide through eight regional branches and three logistics centers.

Is Nihon Generic a public or private company?

Nihon Generic is a private company. It is classified as corporate owned and is currently operating.

When was Nihon Generic founded?

Nihon Generic was founded in 2005. It employs 1 to 10 people.

Where is Nihon Generic based?

Nihon Generic is headquartered in Marunouchi, Japan, in the Asia region.

How does Nihon Generic make money?

Two revenue lines are on record. Prescription Generic Pharmaceutical Products are the primary driver. The others are OTC Pharmaceutical Products.

Who are Nihon Generic's main competitors?

Direct peers on record are Nichi-Iko Pharmaceutical, Sawai Pharmaceutical, Choseido Pharmaceutical and Towa Pharmaceutical. Broad incumbents are Medipal Holdings, Meiji Seika Pharma, Alfresa Corporation, Tsumura & Co. and Suzuken. Nichiko Pharmaceutical is listed as an others.

Does Nihon Generic have an API?

No public API is recorded for Nihon Generic.

What industry is Nihon Generic in?

Nihon Generic's product category is Generic Pharmaceuticals. Its primary akta.pro industry code is HLAIABAH, Generic Finished Dosage Form (FDF) Manufacturing, with a secondary code of HLAIABAD, Oral Solid Dose (OSD) Generics. Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales